X
Search
X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

ZERO’s Statement on House Appropriations Committee Approval of FY18 Defense Bill

June 30, 2017

In 2017 alone, more than 160,000 men across the United States will be diagnosed with prostate cancer, and an estimated 26,730 will die of the disease. Research funding is critical to saving lives impacted by prostate cancer.

Yesterday, the House Appropriations Committee approved the fiscal year 2018 Defense Appropriations bill. This is an important step in preserving the $90 Million in funding allocated for the Peer-Reviewed Prostate Cancer Research Program (PCRP) within the Congressionally-Directed Medical Research Programs. The FY18 funding level matches the current fiscal year funding, which was the first increase to the program in over a decade.

ZERO is pleased to see that Appropriations Chairman Rodney Frelinghuysen, Defense Subcommittee Chairwoman Kay Granger, and the rest of the committee have once again made prostate cancer research a priority and recognized the unique and impactful model of the PCRP. The $90 Million will fund grants to institutions around the country performing vital research. Research funded through the PCRP has led to the development of three life-extending treatments for advanced prostate cancer and one advanced diagnostic in the last six years.

ZERO applauds the committee for their commitment to prostate cancer research. Together, we are making progress toward saving the lives of the one in eight fathers, brothers, and sons who will be diagnosed with prostate cancer in their lifetime. We look forward to working with the Senate Appropriations Committee to ensure that the PCRP maintains its funding level of $90 Million through the rest of the appropriations process.


About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 84 cents of every dollar to research and programs. For more information, visit www.zerocancer.org.